Do analysts prefer VNDA or CALT?

Vanda Pharmaceuticals presently has a consensus price target of $13.70, suggesting a potential upside of 159.47%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to ANRO or VNDA?

In the previous week, Alto Neuroscience had 17 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 20 mentions for Alto Neuroscience and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.13 beat Alto Neuroscience's score of 0.76 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRON or VNDA?

In the previous week, Cronos Group had 1 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 4 mentions for Cronos Group and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.13 beat Cronos Group's score of 0.46 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vanda Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VNDA or ARDX?

In the previous week, Ardelyx had 12 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 15 mentions for Ardelyx and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.13 beat Ardelyx's score of 0.16 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation and earnings, IVA or VNDA?

Vanda Pharmaceuticals has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 191.73 -$400.67M N/A N/A Vanda Pharmaceuticals $216.10M 1.48 -$220.47M -$4.63 N/A

Does the media favor IVA or VNDA?

In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Inventiva. MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 1 mentions for Inventiva. Vanda Pharmaceuticals' average media sentiment score of 1.13 beat Inventiva's score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vanda Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vanda Pharmaceuticals (VNDA) Competitors

$5.28 -0.10 (-1.86%)

As of 08/21/2026 04:00 PM Eastern

Compare

VNDA vs. CALT, ANRO, CRON, ARDX, and IVA

Should you buy Vanda Pharmaceuticals stock or one of its competitors? Vanda Pharmaceuticals's main competitors and comparable companies include Calliditas Therapeutics AB (publ) (CALT), Alto Neuroscience (ANRO), Cronos Group (CRON), Ardelyx (ARDX), and Inventiva (IVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Vanda Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Vanda Pharmaceuticals presently has a consensus price target of $13.70, suggesting a potential upside of 159.47%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Vanda Pharmaceuticals has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Vanda Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.48	-$220.47M	-$4.63	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

In the previous week, Vanda Pharmaceuticals had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Vanda Pharmaceuticals' average media sentiment score of 1.13 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Vanda Pharmaceuticals	Positive
Calliditas Therapeutics AB (publ)	Neutral

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Vanda Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 10 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Alto Neuroscience had 17 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 20 mentions for Alto Neuroscience and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.13 beat Alto Neuroscience's score of 0.76 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alto Neuroscience has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

Alto Neuroscience currently has a consensus target price of $37.25, indicating a potential upside of 8.41%. Vanda Pharmaceuticals has a consensus target price of $13.70, indicating a potential upside of 159.47%. Given Vanda Pharmaceuticals' higher probable upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Alto Neuroscience has higher earnings, but lower revenue than Vanda Pharmaceuticals. Alto Neuroscience is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Vanda Pharmaceuticals	$216.10M	1.48	-$220.47M	-$4.63	N/A

Alto Neuroscience has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Alto Neuroscience's return on equity of -46.46% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-46.46%	-39.09%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Alto Neuroscience beats Vanda Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Cronos Group has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

In the previous week, Cronos Group had 1 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 4 mentions for Cronos Group and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.13 beat Cronos Group's score of 0.46 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vanda Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cronos Group presently has a consensus price target of $2.30, indicating a potential downside of 30.51%. Vanda Pharmaceuticals has a consensus price target of $13.70, indicating a potential upside of 159.47%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cronos Group has a net margin of 39.08% compared to Vanda Pharmaceuticals' net margin of -127.41%. Cronos Group's return on equity of 4.85% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	39.08%	4.85%	4.62%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

8.7% of Cronos Group shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 7.8% of Cronos Group shares are held by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cronos Group has higher earnings, but lower revenue than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59M	8.37	-$9.45M	$0.20	16.55
Vanda Pharmaceuticals	$216.10M	1.48	-$220.47M	-$4.63	N/A

Summary

Cronos Group beats Vanda Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Ardelyx?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Ardelyx had 12 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 15 mentions for Ardelyx and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.13 beat Ardelyx's score of 0.16 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Ardelyx has higher revenue and earnings than Vanda Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.48	-$220.47M	-$4.63	N/A
Ardelyx	$450.89M	2.15	-$61.60M	-$0.22	N/A

Ardelyx has a net margin of -12.35% compared to Vanda Pharmaceuticals' net margin of -127.41%. Ardelyx's return on equity of -36.00% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Ardelyx	-12.35%	-36.00%	-10.77%

Vanda Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Vanda Pharmaceuticals presently has a consensus price target of $13.70, indicating a potential upside of 159.47%. Ardelyx has a consensus price target of $13.90, indicating a potential upside of 257.33%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts clearly believe Ardelyx is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Ardelyx beats Vanda Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Inventiva?

Inventiva (NASDAQ:IVA) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Inventiva. MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 1 mentions for Inventiva. Vanda Pharmaceuticals' average media sentiment score of 1.13 beat Inventiva's score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vanda Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inventiva has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market.

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Inventiva currently has a consensus target price of $16.56, suggesting a potential upside of 253.75%. Vanda Pharmaceuticals has a consensus target price of $13.70, suggesting a potential upside of 159.47%. Given Inventiva's stronger consensus rating and higher possible upside, research analysts clearly believe Inventiva is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Vanda Pharmaceuticals has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	191.73	-$400.67M	N/A	N/A
Vanda Pharmaceuticals	$216.10M	1.48	-$220.47M	-$4.63	N/A

Inventiva has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Inventiva's return on equity of 0.00% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

Summary

Inventiva beats Vanda Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Vanda Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VNDA vs. The Competition

Export

Metric	Vanda Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$319.24M	$12.54B	$7.37B	$12.85B
Dividend Yield	N/A	2.61%	2.53%	11.08%
P/E Ratio	-1.14	789.80	272.60	24.24
Price / Sales	1.48	764.50	618.96	99.81
Price / Cash	N/A	96.77	78.62	53.99
Price / Book	1.45	11.89	13.05	6.20
Net Income	-$220.47M	$2.81B	$3.47B	$348.59M
7 Day Performance	1.15%	1.77%	2.09%	0.08%
1 Month Performance	-1.49%	3.85%	6.64%	3.88%
1 Year Performance	11.16%	6.56%	25.02%	16.98%

Vanda Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VNDA Vanda Pharmaceuticals	2.8065 of 5 stars	$5.28 -1.9%	$13.70 +159.5%	+11.2%	$319.24M	$216.10M	N/A	290	Positive News
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
ANRO Alto Neuroscience	1.6762 of 5 stars	$33.70 +4.9%	$37.25 +10.5%	+779.4%	$1.18B	N/A	N/A	N/A	Analyst Upgrade Analyst Revision High Trading Volume
CRON Cronos Group	1.5452 of 5 stars	$3.15 +0.3%	$2.30 -27.0%	+27.3%	$1.17B	$146.59M	15.75	450
ARDX Ardelyx	3.0279 of 5 stars	$4.06 flat	$14.90 +267.0%	-36.3%	$1.01B	$450.89M	N/A	90	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VNDA) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. CALT, ANRO, CRON, ARDX, and IVA

How does Vanda Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Summary

How does Vanda Pharmaceuticals compare to Alto Neuroscience?

Summary

How does Vanda Pharmaceuticals compare to Cronos Group?

Summary

How does Vanda Pharmaceuticals compare to Ardelyx?

Summary

How does Vanda Pharmaceuticals compare to Inventiva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. CALT, ANRO, CRON, ARDX, and IVA

How does Vanda Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Is VNDA or CALT more profitable?

Do analysts prefer VNDA or CALT?

Which has more volatility and risk, VNDA or CALT?

Which has better valuation and earnings, VNDA or CALT?

Does the media prefer VNDA or CALT?

Do institutionals & insiders hold more shares of VNDA or CALT?

Summary

How does Vanda Pharmaceuticals compare to Alto Neuroscience?

Does the media refer more to ANRO or VNDA?

Which has more volatility and risk, ANRO or VNDA?

Do analysts recommend ANRO or VNDA?

Which has stronger valuation & earnings, ANRO or VNDA?

Is ANRO or VNDA more profitable?

Do institutionals and insiders have more ownership in ANRO or VNDA?

Summary

How does Vanda Pharmaceuticals compare to Cronos Group?

Which has more volatility and risk, CRON or VNDA?

Does the media favor CRON or VNDA?

Do analysts prefer CRON or VNDA?

Is CRON or VNDA more profitable?

Do institutionals & insiders have more ownership in CRON or VNDA?

Which has stronger earnings & valuation, CRON or VNDA?

Summary

How does Vanda Pharmaceuticals compare to Ardelyx?

Do institutionals and insiders believe in VNDA or ARDX?

Does the media prefer VNDA or ARDX?

Which has preferable valuation & earnings, VNDA or ARDX?

Is VNDA or ARDX more profitable?

Which has more risk & volatility, VNDA or ARDX?

Do analysts prefer VNDA or ARDX?

Summary

How does Vanda Pharmaceuticals compare to Inventiva?

Does the media favor IVA or VNDA?

Which has more risk & volatility, IVA or VNDA?

Do institutionals & insiders hold more shares of IVA or VNDA?

Do analysts recommend IVA or VNDA?

Which has higher valuation and earnings, IVA or VNDA?

Is IVA or VNDA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools